Combination cancer therapies can shrink tumors and improve survival outcomes for patients with advanced non-small lung cancer

While pembrolizumab is an approved treatment for patients with stage III non-small cell lung cancer (NSCLC), only some patients respond to this therapy. Treatment failure, researchers say, is often caused by differences in the tumor microenvironment. An ongoing phase II study (KEYNOTE-495/KeyImPaCT) led by a researcher at Yale Cancer Center reveals that combining pembrolizumab with other treatments reduced the size of target tumors, resulting in a higher response rate for patients with advanced NSCLC.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news